<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<HR SIZE="5" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: white">

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report<B>&nbsp;</B>(Date of earliest
event reported):<B>&nbsp;May 22, 2013&#9;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tamir Biotechnology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>0-11088</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 39%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="width: 39%; text-align: center"><FONT STYLE="font-size: 10pt"><B>22-2369085</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5825 Oberlin Drive, San Diego, CA 92121</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices, with
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(732) 823-1003</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant's telephone number, including area
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;(Former name or former
address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">o</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">o </FONT>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">o</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<HR SIZE="3" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: white">

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Item
7.01 Regulation FD Disclosure.</B></FONT><FONT STYLE="background-color: white"><BR>
<BR>
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white; text-align: justify"><FONT STYLE="background-color: white">On
May 22, 2013, an Administrative Law Judge issued an Initial Decision revoking the registration of the common stock of Tamir Biotechnology,
Inc. (the &ldquo;Company&rdquo;) under Section 12(j) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)
because the Company had previously been delinquent in filing periodic reports with the Securities and Exchange Commission (the
&ldquo;Commission&rdquo;). The Initial Decision will become final upon entry by the Commission of an order of finality, which is
expected to occur approximately 21 days following the issuance of the Initial Order. Upon entry of the order of finality by the
Commission, broker-dealers will be prohibited from executing trades in the Company&rsquo;s common stock, and as a result, public
trading of the Company&rsquo;s common stock will cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white; text-align: justify"><FONT STYLE="background-color: white">The
Company is currently considering its options and may seek to re-register its common stock under Section 12 of the Exchange Act
after the Initial Decision becomes final by filing a Form 10 with the Commission. However, there is no assurance that the Company
will resume being a publicly traded company under the Exchange Act. Accordingly, once the Initial Order becomes final, and until
such time, if ever, as the Company effects such re-registration, the disclosure requirements under the Exchange Act, including
the filing of periodic reports and proxy statements, will not be applicable to the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white; text-align: justify"><FONT STYLE="background-color: white">In
May 2013, the Company concluded a confirmatory study regarding the purity and enzymatic activity of ONCONASE&reg; (ranpirnase).
The study confirmed that as shown in the proof-of-concept skin penetration studies performed by the Company in 2012, ONCONASE&reg;
is indeed capable of being delivered transdermally and that ONCONASE&reg; remained active following such delivery throughout the
length of the evaluation across the full range of ranpirnase concentrations tested. The Company believes that the purity and activity
profiles of ONCONASE&reg; appear to be acceptable to permit further non-clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As previously reported,
the Company is a party to a Memorandum of Understanding (&ldquo;MOU&rdquo;), with US Pharmacia International, Inc. (together with
Unilab and its affiliates, &ldquo;USPI&rdquo;), under which USPI is to be granted exclusive marketing, sales, and distribution
rights for ONCONASE<SUP>&reg;</SUP>&nbsp;for the treatment of Human Papillioma Virus (HPV) in Europe in consideration of $1 million
(the &ldquo;License Fee&rdquo;) to be paid by USPI to the Company as milestones are achieved. An initial payment of $405,000 towards
the License Fee was made by USPI to the Company in December, 2011, and an additional payment in the amount of $95,000 was made
to the Company in 2012 following the results of the 2012 <FONT STYLE="background-color: white">proof-of-concept study</FONT>. USPI
and the Company have agreed that the results of the confirmatory study described above entitle the Company to an additional $100,000
milestone payment, which amount was paid by USPI to the Company in June 2013, bringing the total payments made to the Company under
the MOU to $600,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&#9; &#9;TAMIR BIOTECHNOLOGY, INC.&#9;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&#9; &#9; &#9;</P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">Date: June 11, 2013&#9; &#9;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">By:&#9;<U> /s/ <FONT STYLE="color: black">Joanne Barsa<FONT STYLE="background-color: white">&#9;&#9;&#9;</FONT></FONT></U></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><U><FONT STYLE="color: black"><FONT STYLE="background-color: white"></FONT></FONT></U>Name:
&#9;<FONT STYLE="color: black">Joanne Barsa</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">Title: Chief Financial Officer and Secretary</P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "acelform8k130522.htm", "description": "TAMIR BIOTECHNOLOGY, INC. FORM 8-K", "secsgml_size_bytes": 14242}]
{"company-data": {"conformed-name": "Tamir Biotechnology, Inc.", "cik": "0000708717", "assigned-sic": "2836", "irs-number": "222369085", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11088", "film-number": "13906105"}, "business-address": {"street1": "300 ATRIUM DRIVE", "city": "SOMERSET", "state": "NJ", "zip": "08873", "phone": "732-652-4525"}, "mail-address": {"street1": "300 ATRIUM DRIVE", "city": "SOMERSET", "state": "NJ", "zip": "08873"}, "former-company": {"former-conformed-name": "ALFACELL CORP", "date-changed": "19920703"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report
(Date of earliest
event reported):
May 22, 2013
Tamir Biotechnology, Inc.
(Exact name of registrant as specified in its
charter)
0-11088
(Commission File Number)
Delaware
22-2369085
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
5825 Oberlin Drive, San Diego, CA 92121
(Address of principal executive offices, with
zip code)
(732) 823-1003
(Registrant's telephone number, including area
code)
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
On
May 22, 2013, an Administrative Law Judge issued an Initial Decision revoking the registration of the common stock of Tamir Biotechnology,
Inc. (the "Company") under Section 12(j) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")
because the Company had previously been delinquent in filing periodic reports with the Securities and Exchange Commission (the
"Commission"). The Initial Decision will become final upon entry by the Commission of an order of finality, which is
expected to occur approximately 21 days following the issuance of the Initial Order. Upon entry of the order of finality by the
Commission, broker-dealers will be prohibited from executing trades in the Company's common stock, and as a result, public
trading of the Company's common stock will cease.
The
Company is currently considering its options and may seek to re-register its common stock under Section 12 of the Exchange Act
after the Initial Decision becomes final by filing a Form 10 with the Commission. However, there is no assurance that the Company
will resume being a publicly traded company under the Exchange Act. Accordingly, once the Initial Order becomes final, and until
such time, if ever, as the Company effects such re-registration, the disclosure requirements under the Exchange Act, including
the filing of periodic reports and proxy statements, will not be applicable to the Company.
In
May 2013, the Company concluded a confirmatory study regarding the purity and enzymatic activity of ONCONASE® (ranpirnase).
The study confirmed that as shown in the proof-of-concept skin penetration studies performed by the Company in 2012, ONCONASE®
is indeed capable of being delivered transdermally and that ONCONASE® remained active following such delivery throughout the
length of the evaluation across the full range of ranpirnase concentrations tested. The Company believes that the purity and activity
profiles of ONCONASE® appear to be acceptable to permit further non-clinical studies.
As previously reported,
the Company is a party to a Memorandum of Understanding ("MOU"), with US Pharmacia International, Inc. (together with
Unilab and its affiliates, "USPI"), under which USPI is to be granted exclusive marketing, sales, and distribution
rights for ONCONASE
®
for the treatment of Human Papillioma Virus (HPV) in Europe in consideration of $1 million
(the "License Fee") to be paid by USPI to the Company as milestones are achieved. An initial payment of $405,000 towards
the License Fee was made by USPI to the Company in December, 2011, and an additional payment in the amount of $95,000 was made
to the Company in 2012 following the results of the 2012
proof-of-concept study
. USPI
and the Company have agreed that the results of the confirmatory study described above entitle the Company to an additional $100,000
milestone payment, which amount was paid by USPI to the Company in June 2013, bringing the total payments made to the Company under
the MOU to $600,000.
-
2
-
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TAMIR BIOTECHNOLOGY, INC.
Date: June 11, 2013
By:
/s/
Joanne Barsa
Name:
Joanne Barsa
Title: Chief Financial Officer and Secretary